Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)
The tumour harbours common EGFR mutations (Del19, L858R) at start of first-line treatment
Patients who initiated second-line osimertinib treatment for acquired T790M mutation at least 10 months prior to data entry, AND who were treated with afatinib (Gi(l)otrif®) in the first-line
Patients treated with osimertinib within an EAP/CUP or regular clinical practice
Age ≥ 18 years
Signed and dated written informed consent per regulations (Exemption of a written informed consent for NIS based on existing data in countries per local regulations and legal requirements)
You may not be if
Patients who received drug(s) other than osimertinib as the second-line treatment and/or patients who received drug(s) other than afatinib (Gi(l)otrif®) as the first-line treatment
Patients with active brain metastases at start of treatment (either afatinib/Gi(l)otrif® or osimertinib)
